Aims To project the number of cases with age-related macular degeneration (AMD) and the numbers with attributable sight loss in the UK in 2010–2020, taking into account the expected beneficial effect of the new anti-vascular endothelial growth factor (VEGF) therapies.
Methods A ‘system dynamics’ approach was used in constructing the model to simulate the dynamics of the disease in large populations. The model computed the pool of affected cases over the simulation period, taking into account the expected demographic changes. Other determinants taken into account included: prevalence; incidence; mortality; and the expected efficacy and coverage of anti-VEGF treatment.
Results In the UK, 608 213 persons in 2010 are estimated to have AMD, and this is expected to increase to 755 867 by the end of the decade. Numbers with sight loss from AMD are expected to rise from 223 224 in 2010 to 291 982 by 2020. Cases with sight loss due to neovascular AMD are expected to increase from 145 697 to 189 890 by the end of the decade.
Conclusions The model predicts that the beneficial effects of the treatment would be outweighed by the strong anticipated demographic ‘ageing’ effect. This reaffirms the importance of continuing efforts to develop more effective and more broadly applicable therapies for AMD.
- Macular degeneration
- reduced vision
- population dynamics
- Computerised models
Statistics from Altmetric.com
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Funding The study was funded by the Royal National Institute of Blind People (RNIB).
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.